separation of the  vitreous detachment in my right eye with a little bleading; Eye bleeding; MIgraine arc aura in the left eye; Aura  in left eye duration 5 min periodically; Color blotches in left eye duration 5 min periodically; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VITREOUS DETACHMENT (separation of the  vitreous detachment in my right eye with a little bleading) and EYE HAEMORRHAGE (Eye bleeding) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 007B21A and 024M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug allergy (allergic to Seldane.), Drug allergy (strong reactions to opiates), Kidney function abnormal, Enlarged prostate since 2019 and Calcium pyrophosphate dihydrate deposition disease. Concomitant products included LORATADINE (CLARITINE) for Allergy, COLCHICINE from 2019 to an unknown date for Calcium pyrophosphate dihydrate deposition disease, TAMSULOSIN HYDROCHLORIDE (MAXFLO) from 2020 to an unknown date for Enlarged prostate, CALCIUM CITRATE from 2010 to an unknown date for Osteopenia, COLECALCIFEROL (D3) for an unknown indication.   On 25-Feb-2021 at 5:45 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021 at 3:25 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 08-Apr-2021, the patient experienced AURA (Aura  in left eye duration 5 min periodically) and CHROMATOPSIA (Color blotches in left eye duration 5 min periodically). On 16-Apr-2021, the patient experienced MIGRAINE WITH AURA (MIgraine arc aura in the left eye). On an unknown date, the patient experienced VITREOUS DETACHMENT (separation of the  vitreous detachment in my right eye with a little bleading) (seriousness criterion medically significant) and EYE HAEMORRHAGE (Eye bleeding) (seriousness criterion medically significant). The patient was treated with AZELASTINE for Nasal congestion, at an unspecified dose and frequency. On 20-Apr-2021, AURA (Aura  in left eye duration 5 min periodically) and CHROMATOPSIA (Color blotches in left eye duration 5 min periodically) had resolved. At the time of the report, VITREOUS DETACHMENT (separation of the  vitreous detachment in my right eye with a little bleading), EYE HAEMORRHAGE (Eye bleeding) and MIGRAINE WITH AURA (MIgraine arc aura in the left eye) outcome was unknown.            Treatment information was not reported.  Ophthalmologist advised the patient that no procedures were required for the event, separation of the  vitreous detachment in my right eye with a little bleeding.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 01-Jun-2021: A follow up was received on 10-MAY-2021 Which had patient's demographics, medical history, concomitant medications and event (Migraine Aura). On 04-Jul-2021: No new information was provided. On 05-Jul-2021: Additional event, separation of the  vitreous detachment in my right eye with a little bleading, was provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.